Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review

References

• Petrosillo N. Infections: the emergency of the new millennium. In: Nuclear Medicine in Infectious Diseases. Springer; 2020:1–8.
   Google Scholar
• Lutgring JD. Carbapenem-resistant Enterobacteriaceae: an emerging bacterial threat. In: Seminars in Diagnostic Pathology. Elsevier; 2019.
   Google Scholar
• Van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin. 2016;30(2):377–390.
   PubMed Web of Science ®Google Scholar
• Spera AM, Esposito S, Pagliano P. Emerging antibiotic resistance: carbapenemase-producing enterobacteria. Bad new bugs, still no new drugs. Le Infezioni Medicina. 2019;27(4):357–364.
   Google Scholar
• O’Malley PA. A most dangerous outbreak: New Delhi metallo-β-lactamase-1 carbapenemase-producing Enterobacteriaceae. Clin Nurse Special. 2020;34(1):13–16. doi:10.1097/NUR.0000000000000497
   Web of Science ®Google Scholar
• World Health Organization. WHO Priority Pathogens List for R&D of New Antibiotics. Geneva, Switzerland: World Health Organization; 2017.
   Google Scholar
• Gordon MA, Feasey NA, Nyirenda TS, Graham SM. Nontyphoid salmonella disease. In: Hunter’s Tropical Medicine and Emerging Infectious Diseases. Elsevier; 2020:500–506.
   Google Scholar
• Centres for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. US Department of Health and Human Services, Centres for Disease Control and Prevention; 2019.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey R, et al. Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• Goic-Barisic I, Seruga Music M, Kovacic A, Tonkic M, Hrenovic J. Pan drug-resistant environmental isolate of Acinetobacter baumannii from Croatia. Microb Drug Resist. 2017;23(4):494–496. doi:10.1089/mdr.2016.022927792476
   PubMed Web of Science ®Google Scholar
• Li L, Yu T, Ma Y, et al. The genetic structures of an Extensively Drug Resistant (XDR) Klebsiella pneumoniae and its plasmids. Front Cell Infect Microbiol. 2018;8:446. doi:10.3389/fcimb.2018.0044630662878
   PubMed Web of Science ®Google Scholar
• Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One. 2015;10(8):e0135745. doi:10.1371/journal.pone.013574526284519
   PubMed Web of Science ®Google Scholar
• Boutal H, Vogel A, Bernabeu S, et al. A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP-and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(4):909–915. doi:10.1093/jac/dkx52129365094
   PubMed Web of Science ®Google Scholar
• Lee C-M, Lai -C-C, Chiang H-T, et al. Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. J Microbiol Immunol Infect. 2017;50(2):133–144. doi:10.1016/j.jmii.2016.12.00128373038
   PubMedGoogle Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079–17. doi:10.1128/CMR.00079-1729444952
   PubMed Web of Science ®Google Scholar
• Pana ZD, Zaoutis T. Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? F1000Research. 2018;7:1347. doi:10.12688/f1000research.14822.1
   Google Scholar
• Kohlenberg A, Weitzel-Kage D, Van der Linden P, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J Hosp Infect. 2010;74(4):350–357. doi:10.1016/j.jhin.2009.10.02420170982
   PubMed Web of Science ®Google Scholar
• Cezário RC, De Morais LD, Ferreira JC, Costa-Pinto RM, da Costa Darini AL, Gontijo-Filho PP. Nosocomial outbreak by imipenem-resistant metallo-β-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Infecc Microbiol Clin. 2009;27(5):269–274. doi:10.1016/j.eimc.2008.09.00919386392
   PubMed Web of Science ®Google Scholar
• D’Angelo RG, Johnson JK, Bork JT, Heil EL. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17(7):953–967. doi:10.1517/14656566.2016.115453826891857
   PubMed Web of Science ®Google Scholar
• Diene SM, Rolain J-M. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2014;20(9):831–838. doi:10.1111/1469-0691.1265524766097
   PubMed Web of Science ®Google Scholar
• Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5(1):21. doi:10.1186/s13613-015-0061-0
   Web of Science ®Google Scholar
• Blanquart F, Lehtinen S, Lipsitch M, Fraser C. The evolution of antibiotic resistance in a structured host population. J Royal Soc Interface. 2018;15(143):20180040. doi:10.1098/rsif.2018.0040
   Web of Science ®Google Scholar
• Ranjbar R, Farahani A. Shigella: antibiotic-resistance mechanisms and new horizons for treatment. Infect Drug Resist. 2019;12:3137. doi:10.2147/IDR.S21975531632102
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• Jarvis KG, Daquigan N, White JR, et al. Microbiomes associated with foods from plant and animal sources. Front Microbiol. 2018;9:2540. doi:10.3389/fmicb.2018.0254030405589
   PubMed Web of Science ®Google Scholar
• Vergara-López S, Domínguez M, Conejo M, Pascual Á, Rodríguez-Baño J. Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo-β-lactamase-producing Klebsiella oxytoca. Clin Microbiol Infect. 2013;19(11):E490–E8. doi:10.1111/1469-0691.1228823829434
   PubMed Web of Science ®Google Scholar
• Singh G. Hospital Infection Control Guidelines: Principles and Practice. Jaypee Brothers Publishers; 2012.
   Google Scholar
• Tzouvelekis L, Markogiannakis A, Psichogiou M, Tassios P, Daikos G. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707. doi:10.1128/CMR.05035-1123034326
   PubMed Web of Science ®Google Scholar
• Mehta Y, Gupta A, Todi S, et al. Guidelines for prevention of hospital acquired infections. Indian J Crit Care Med. 2014;18(3):149. doi:10.4103/0972-5229.12870524701065
   PubMedGoogle Scholar
• Logan LK, Medernach RL, Rispens JR, et al. Community origins and regional differences highlight risk of plasmid-mediated fluoroquinolone resistant Enterobacteriaceae infections in children. Pediatr Infect Dis J. 2019;38(6):595. doi:10.1097/INF.000000000000220530281548
   PubMed Web of Science ®Google Scholar
• Borgia S, Lastovetska O, Richardson D, et al. Outbreak of carbapenem-resistant Enterobacteriaceae containing bla NDM-1, Ontario, Canada. Clin Infect Dis. 2012;55(11):e109–e17. doi:10.1093/cid/cis73722997214
   PubMed Web of Science ®Google Scholar
• Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11(5):355–362. doi:10.1016/S1473-3099(11)70059-721478057
   PubMed Web of Science ®Google Scholar
• Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51. doi:10.1038/nrmicro338025435309
   PubMed Web of Science ®Google Scholar
• Miró E, Grünbaum F, Gómez L, et al. Characterization of aminoglycoside-modifying enzymes in Enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb Drug Resist. 2013;19(2):94–99. doi:10.1089/mdr.2012.012523206280
   PubMed Web of Science ®Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2018;6(1):1. doi:10.3390/medsci6010001
   Google Scholar
• Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014;20(9):821–830. doi:10.1111/1469-0691.1271924930781
   PubMed Web of Science ®Google Scholar
• Siefert JL. Man and his spaceships: vehicles for extraterrestrial colonization? Mob Genet Elements. 2012;2(6):272–278. doi:10.4161/mge.2323823481263
   PubMedGoogle Scholar
• Liu -Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168. doi:10.1016/S1473-3099(15)00424-726603172
   PubMed Web of Science ®Google Scholar
• Falgenhauer L, Waezsada S-E, Yao Y, et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect Dis. 2016;16(3):282–283. doi:10.1016/S1473-3099(16)00009-826774242
   PubMed Web of Science ®Google Scholar
• Smith H, Bossers A, Harders F, et al. Characterization of epidemic IncI1-Iγ plasmids harboring ambler class A and C genes in Escherichia coli and Salmonella enterica from animals and humans. Antimicrob Agents Chemother. 2015;59(9):5357–5365. doi:10.1128/AAC.05006-1426100710
   PubMed Web of Science ®Google Scholar
• Exner M, Bhattacharya S, Christiansen B, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? GMS Hygiene Infect Control. 2017;12. doi:10.3205/dgkh000290
   Web of Science ®Google Scholar
• McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. In: Antimicrobial Resistance in Bacteria from Livestock and Companion Animals. Wiley Online Libraray; 2018:521–547.
   Google Scholar
• Vink JP, Otter JA, Edgeworth JD. Carbapenemase-producing Enterobacteriaceae–once positive always positive? Curr Opin Gastroenterol. 2020;36(1):9–16. doi:10.1097/MOG.000000000000059631633563
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2):e00047–19. doi:10.1128/CMR.00047-1932102899
   PubMed Web of Science ®Google Scholar
• Weiner L, Webb A, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301. doi:10.1017/ice.2016.17427573805
   PubMed Web of Science ®Google Scholar
• Weist K, Högberg LD. ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe. Eurosurveillance. 2016;21(46):30401. doi:10.2807/1560-7917.ES.2016.21.46.30399
   Web of Science ®Google Scholar
• Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50(3):364–373. doi:10.1086/64986520041768
   PubMed Web of Science ®Google Scholar
• Adler A, Hussein O, Ben-David D, et al. Persistence of Klebsiella pneumoniae ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008–13. J Antimicrob Chemother. 2015;70(1):89–92. doi:10.1093/jac/dku33325204343
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis. 2007;59(4):425–432. doi:10.1016/j.diagmicrobio.2007.05.00917662557
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005). Diagn Microbiol Infect Dis. 2006;56(4):367–372. doi:10.1016/j.diagmicrobio.2006.07.00417020798
   PubMed Web of Science ®Google Scholar
• Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 US hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother. 2013;57(7):3012–3020. doi:10.1128/AAC.02252-1223587957
   PubMed Web of Science ®Google Scholar
• Kotb S, Lyman M, Ismail G, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare–associated Infections Surveillance Data, 2011–2017. Antimicrob Resist Infect Control. 2020;9(1):1–9. doi:10.1186/s13756-019-0639-731908772
   PubMed Web of Science ®Google Scholar
• Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2(1):1–13. doi:10.1186/2047-2994-2-3123305311
   PubMed Web of Science ®Google Scholar
• Baran I, Aksu N. Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey. Ann Clin Microbiol Antimicrob. 2016;15(1):1–11. doi:10.1186/s12941-016-0136-226786830
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Cox HL, Kitchel B, et al. Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. MBio. 2011;2(6):e00204–11. doi:10.1128/mBio.00204-1122045989
   PubMed Web of Science ®Google Scholar
• Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2017;61(7):e00465–17. doi:10.1128/AAC.00465-1728483953
   PubMed Web of Science ®Google Scholar
• Partina I, Kalinogorskaya O, Kojima S, et al. Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia. Jpn J Antibiot. 2016;69(1):41–51.27290829
   PubMedGoogle Scholar
• Bailey AL, Armstrong T, Dwivedi H-P, et al. Multicenter evaluation of the Etest gradient diffusion method for ceftolozane-tazobactam susceptibility testing of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018;56(9):e00717–18. doi:10.1128/JCM.00717-1829976590
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010–2013). Diagn Microbiol Infect Dis. 2015;83(2):183–186. doi:10.1016/j.diagmicrobio.2015.06.01126164275
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Khanduri N, Agarwal R. Comparative evaluation of rapid colorimetric methods for detecting carbapenemase enzymes in Gram-negative bacilli. Indian J Microbiol Res. 2017;4:263–266.
   Google Scholar
• Nair PK, Vaz MS. Prevalence of carbapenem resistant Enterobacteriaceae from a tertiary care hospital in Mumbai, India. J Microbiol Infect Dis. 2013;3(04):207–210. doi:10.5799/ahinjs.02.2013.04.0110
   Google Scholar
• Khare V, Gupta P, Haider F, Begum R. Study on MICs of tigecycline in clinical isolates of carbapenem resistant Enterobacteriaceae (CRE) at a tertiary care centre in North India. JCDR. 2017;11(3):DC18.
   Web of Science ®Google Scholar
• Amjad A, Mirza IA, Abbasi S, Farwa U, Malik N, Zia F. Modified Hodge test: a simple and effective test for detection of carbapenemase production. Iran J Microbiol. 2011;3(4):189.22530087
   PubMedGoogle Scholar
• Jamal WY, Albert MJ, Rotimi VO, Galdiero M. High prevalence of New Delhi metallo-β-lactamase-1 (NDM-1) producers among carbapenem-resistant Enterobacteriaceae in Kuwait. PLoS One. 2016;11(3):e0152638. doi:10.1371/journal.pone.015263827031521
   PubMed Web of Science ®Google Scholar
• Li Y, Sun Q-L, Shen Y, et al. Rapid increase in prevalence of carbapenem-resistant Enterobacteriaceae (CRE) and emergence of colistin resistance gene mcr-1 in CRE in a hospital in Henan, China. J Clin Microbiol. 2018;56(4):e01932–17. doi:10.1128/JCM.01932-1729386265
   PubMed Web of Science ®Google Scholar
• Kandeel A. Epidemiology of carbapenemase producing Enterobacteriaceae in a general hospital. J Microbiol Infect Dis. 2015;5(2):57–62. doi:10.5799/ahinjs.02.2015.02.0177
   Google Scholar
• Zaidah AR, Mohammad NI, Suraiya S, Harun A. High burden of Carbapenem-resistant Enterobacteriaceae (CRE) fecal carriage at a teaching hospital: cost-effectiveness of screening in low-resource setting. Antimicrob Resist Infect Control. 2017;6(1):1–6. doi:10.1186/s13756-017-0200-5
   Web of Science ®Google Scholar
• Almugadam B, Ali N, Ahmed A, Ahmed E, Wang L. Prevalence and antibiotics susceptibility patterns of carbapenem resistant Enterobacteriaceae. J Bacteriol Mycol Open Access. 2018;6(3):187–190.
   Google Scholar
• Paveenkittiporn W, Lyman M, Biedron C, et al. Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016–2018. Antimicrob Resist Infect Control. 2021;10(1):1–8. doi:10.1186/s13756-021-00950-733407871
   PubMed Web of Science ®Google Scholar
• Legese MH, Weldearegay GM, Asrat D. Extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae among Ethiopian children. Infect Drug Resist. 2017;10:27. doi:10.2147/IDR.S12717728182124
   PubMed Web of Science ®Google Scholar
• Khalil HS, Wahab MAAE. Risk factors, phenotypic and genotypic characterization of carbapenem resistant Enterobacteriaceae in Tanta University Hospitals, Egypt. Int J Infect Control. 2016;12(2). doi:10.3396/ijic.v12i2.15905
   Google Scholar
• Camara M, Mane MT, Ba-Diallo A, et al. Extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae clinical isolates in a Senegalese teaching hospital: a cross sectional study. Afri J Microbiol Res. 2017;11(44):1600–1605. doi:10.5897/AJMR2017.8716
   Google Scholar
• El Wartiti MA, Bahmani F-Z, Elouennass M, Benouda A. Prevalence of carbapenemase-producing Enterobacteriaceae in a University Hospital in Rabat, Morocco: a 19-months prospective study. Int Arab J Antimicrob Agents. 2012;2(3):1–6.
   Google Scholar
• World Health Organization. Antimicrobial Resistance Global Report on Surveillance: 2014 Summary. World Health Organization; 2014.
   Google Scholar
• Khabbaz RF, Moseley RR, Steiner RJ, Levitt AM, Bell BP. Challenges of infectious diseases in the USA. Lancet. 2014;384(9937):53–63. doi:10.1016/S0140-6736(14)60890-424996590
   PubMed Web of Science ®Google Scholar
• Elliott W, Chan J. Plazomicin injection (Zemdri). Intern Med Alert. 2018;40(15).
   Google Scholar
• Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–597. doi:10.1016/j.ijantimicag.2016.09.01027793510
   PubMed Web of Science ®Google Scholar
• Shankar C, Nabarro LE, Anandan S, Veeraraghavan B. Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant gram–negative organisms? Microb Drug Resist. 2017;23(4):437–446. doi:10.1089/mdr.2016.004327564414
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA, editors. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase–producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clinic Proceedings; Elsevier; 2011.
   Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950.22752516
   PubMed Web of Science ®Google Scholar
• Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014;26:51–56. doi:10.1016/j.ijid.2014.05.01224998423
   PubMed Web of Science ®Google Scholar
• Tan X, Kim HS, Baugh K, et al. Therapeutic options for metallo-β-lactamase-producing enterobacterales. Infect Drug Resist. 2021;14:125. doi:10.2147/IDR.S24617433500635
   PubMed Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(Supplement_7):S538–S543. doi:10.1093/cid/ciz82631724047
   PubMed Web of Science ®Google Scholar
• Li J, Learoyd M, Qiu F, Zhu L, Edeki T. A randomized, Phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime-avibactam in healthy Chinese subjects. Clin Drug Investig. 2016;36(2):119–126. doi:10.1007/s40261-015-0347-x
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–177. doi:10.1007/s40265-013-0013-723371303
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588. doi:10.1007/s40265-016-0545-826863149
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151. doi:10.3389/fpubh.2019.0015131245348
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–285. doi:10.1016/j.ijantimicag.2016.02.00127013000
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine. 2016;95(11):e3126. doi:10.1097/MD.000000000000312626986165
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002–3004. doi:10.1128/AAC.01420-1021422205
   PubMed Web of Science ®Google Scholar
• de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–3169. doi:10.1128/AAC.03042-1526926648
   PubMed Web of Science ®Google Scholar
• Landman D, Babu E, Shah N, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother. 2010;65(10):2123–2127. doi:10.1093/jac/dkq27820667885
   PubMed Web of Science ®Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett. 2014;24(3):780–785. doi:10.1016/j.bmcl.2013.12.10124433862
   PubMed Web of Science ®Google Scholar
• Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163–17. doi:10.1128/AAC.02163-1729311072
   PubMed Web of Science ®Google Scholar
• Barnes MD, Taracila MA, Good CE, et al. Nacubactam enhances meropenem activity against carbapenem-resistant Klebsiella pneumoniae producing KPC. Antimicrob Agents Chemother. 2019;63(8):e00432–19. doi:10.1128/AAC.00432-1931182530
   PubMed Web of Science ®Google Scholar
• Saqib S, Munis MFH, Zaman W, et al. Synthesis, characterization and use of iron oxide nano particles for antibacterial activity. Microsc Res Tech. 2019;82(4):415–420. doi:10.1002/jemt.2318230565799
   PubMed Web of Science ®Google Scholar
• Jamal M, Chaudhry WN, Hussain T, Das CR, Andleeb S. Characterization of new Myoviridae bacteriophage WZ1 against multi‐drug resistant (MDR) Shigella dysenteriae. J Basic Microbiol. 2015;55(4):420–431. doi:10.1002/jobm.20140068825557472
   PubMed Web of Science ®Google Scholar
• Obiero CW, Ndiaye AG, Sciré AS, et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front Immunol. 2017;8:1884. doi:10.3389/fimmu.2017.0188429375556
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115–20. doi:10.1128/CMR.00115-20
   PubMed Web of Science ®Google Scholar
• Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE, Chifiriuc MC. Present and future perspectives on therapeutic options for carbapenemase-producing Enterobacterales infections. Microorganisms. 2021;9(4):730. doi:10.3390/microorganisms904073033807464
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e83.33106864
   PubMed Web of Science ®Google Scholar
• Jankauskaitŀ V, Vitkauskienŀ A, Lazauskas A, Baltrusaitis J, Prosyŀevas I, Andruleviŀius M. Bactericidal effect of graphene oxide/Cu/Ag nanoderivatives against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus. Int J Pharm. 2016;511(1):90–97. doi:10.1016/j.ijpharm.2016.06.12127370911
   PubMed Web of Science ®Google Scholar
• Babaei S, Bajelani F, Mansourizaveleh O, Abbasi A, Oubari F. A study of the bactericidal effect of copper oxide nanoparticles on Shigella sonnei and Salmonella typhimurium. J Babol Univ Med Sci. 2017;19(11):76–81.
   Google Scholar
• Jin X, Chen Q, Shen F, et al. Resistance Evolution of Hypervirulent Carbapenem-resistant Klebsiella pneumoniae ST11 during Treatment with Tigecycline and Polymyxin. Emerg Microbes Infect. 2021;10(just–accepted):1–29.33356979
   PubMed Web of Science ®Google Scholar
• Pozsgay V, Kubler-Kielb J, Schneerson R, Robbins JB. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci. 2007;104(36):14478–14482. doi:10.1073/pnas.070696910417726093
   PubMed Web of Science ®Google Scholar
• DeLaine BC, Wu T, Grassel CL, et al. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. FEMS Pathogens Dis. 2016;74(5):ftw034. doi:10.1093/femspd/ftw034
   Web of Science ®Google Scholar
• Mitobe J, Sinha R, Mitra S, et al. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype. PLoS Negl Trop Dis. 2017;11(7):e0005728. doi:10.1371/journal.pntd.000572828727722
   PubMed Web of Science ®Google Scholar
• Wu Y, Chakravarty S, Li M, Wai TT, Hoffman SL, Sim BKL. Development of a live attenuated bivalent oral vaccine against Shigella sonnei shigellosis and typhoid fever. J Infect Dis. 2017;215(2):259–268. doi:10.1093/infdis/jiw52827803169
   PubMed Web of Science ®Google Scholar
• Kaminski R, Wu M, Turbyfill K, et al. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. Clin Vaccine Immunol. 2014;21(3):366–382. doi:10.1128/CVI.00683-1324403527
   PubMedGoogle Scholar